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Abstract: Hypoxia-inducible-factor-2α (HIF-2α) and HIF-2 degrading prolyl-hydroxylases (PHD) are
key regulators of adaptive hypoxic responses i.e., in acute respiratory distress syndrome (ARDS).
Specifically, functionally active genetic variants of HIF-2α (single nucleotide polymorphism (SNP)
[ch2:46441523(hg18)]) and PHD2 (C/T; SNP rs516651 and T/C; SNP rs480902) are associated with
improved adaptation to hypoxia i.e., in high-altitude residents. However, little is known about these
SNPs’ prevalence in Caucasians and impact on ARDS-outcome. Thus, we tested the hypotheses that
in Caucasian ARDS patients SNPs in HIF-2α or PHD2 genes are (1) common, and (2) independent risk
factors for 30-day mortality. After ethics-committee approval, 272 ARDS patients were prospectively
included, genotyped for PHD2 (Taqman SNP Genotyping Assay) and HIF-2α-polymorphism
(restriction digest + agarose-gel visualization), and genotype dependent 30-day mortality was
analyzed using Kaplan-Meier-plots and multivariate Cox-regression analyses. Frequencies were
99.62% for homozygous HIF-2α CC-carriers (CG: 0.38%; GG: 0%), 2.3% for homozygous PHD2
SNP rs516651 TT-carriers (CT: 18.9%; CC: 78.8%), and 3.7% for homozygous PHD2 SNP rs480902
TT-carriers (CT: 43.9%; CC: 52.4%). PHD2 rs516651 TT-genotype in ARDS was independently
associated with a 3.34 times greater mortality risk (OR 3.34, CI 1.09–10.22; p = 0.034) within 30-days,
whereas the other SNPs had no significant impact (p = ns). The homozygous HIF-2α GG-genotype
was not present in our Caucasian ARDS cohort; however PHD2 SNPs exist in Caucasians, and PHD2
rs516651 TT-genotype was associated with an increased 30-day mortality suggesting a relevance for
adaptive responses in ARDS.
Keywords: acute respiratory distress syndrome; hypoxia inducible factors; prolylhydroxylases;
genetic variants; polymorphism
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1. Introduction
Acute respiratory distress syndrome (ARDS) is a life-threatening disease characterized by
an acute-onset, progressive, hypoxic condition with radiographic bilateral lung infiltration, e.g.,
due to various pathogens, but not due to hydrostatic pulmonary edema. Thus, acute respiratory
distress syndrome (ARDS) results in a highly impaired pulmonary function and hypoxemia [1].
A draft definition proposed three mutually exclusive categories of ARDS based on the degree of
hypoxemia: mild (PaO2/FIO2 ≤ 300 mmHg), moderate (PaO2/FIO2 ≤ 200 mmHg), and severe
(PaO2/FIO2 ≤ 100 mmHg). ARDS is most often due to direct injury to the lung (e.g., pneumonia
and gastric aspiration) or indirect injury (e.g., sepsis and pancreatitis) [2]. However, ARDS can also
develop following trauma or inhalation of toxic gases like ozone [3]. Thus, ARDS is characterized by a
strong inflammatory response and impaired oxygenation due to a ventilation-perfusion mismatch [4],
resulting in pulmonary vasoconstriction caused by the Euler-Liljestrand mechanism. This mechanism,
while being helpful in compensating for regional ventilation abnormalities, aggravates hypoxemia
in ARDS due to a further increase in pulmonary artery pressure. Of note, in ARDS patients severe
pulmonary hypertension can even lead to right heart failure and death. Whereas the Euler-Liljestrand
mechanism in ARDS increases pulmonary artery hypertension and hypoxemia, counter regulating
mechanisms are activated as well [5]. Key regulators of the hypoxic response are the so-called
hypoxia inducible factors (HIF) and HIF degrading prolylhydroxylases (PHD). HIF and PHD are of
importance both in hypoxia and inflammation i.e., important during human hypoxemia and profound
inflammatory response in ARDS [6,7]. In particular, the HIF-2 pathway is involved in a multitude of
biological processes impacting on pulmonary hypertension, erythropoietin synthesis, iron metabolism,
bone marrow microenvironment, and tumor progress [8–11]. Alterations of constitutively activated
HIF-2α are associated with an increased risk for neuroendocrine tumors [12,13]. Furthermore, HIF-2α
is implicated in the pulmonary regulation of thrombo-spondin-1 and contributes to pulmonary artery
hypertension-driven vascular remodeling and vasoconstriction [14]. Thus, differences in HIF-2α
activity or HIF degrading prolylhydroxylases might influence the pulmonary artery hypertension
counterregulating effects of hypoxemia, and thus alter patients’ outcome.
Recently, functionally active genetic variants were identified both in the HIF-2α (C/T;
Single Nucleotide Polymorphism SNP C/G [ch2: 46441523(hg18)] and the PHD2 genes (C/T;
SNP rs516651 and T/C; SNP rs480902). These genetic variants were found to be associated with
erythrocytosis, pulmonary hypertension, and chronic mountain sickness, respectively [10,15–17].
However, it is unknown whether these genetic variants impact on the outcome in ARDS patients.
Accordingly, we tested the hypotheses that (1) SNPs in HIF-2α or PHD2 genes are common in
Caucasians, and (2) they are an independent risk factor for 30-day mortality in ARDS.
2. Results
2.1. Hypoxia Inducible Factor-2α (C/G SNP [ch2: 46441523(hg18)]) Polymorphism
Frequencies were 99.62% for the homozygous CC-genotype, 0.38% heterozygous CG-genotype,
and 0% for homozygous GG-genotype. Since none of the ARDS patients in our cohort carried the
homozygous GG-genotype no further statistical analyses were performed. In healthy blood donor
controls we found the same distribution of genotypes. Thus, the HIF-2α GG-genotype was neither
present in our ARDS cohort of Caucasian heritage nor in healthy controls.
2.2. Prolylhydroxlase 2 (C/T; rs516651) Polymorphism
Allele frequencies were 2.3% for homozygous TT-genotype, 18.9% for heterozygous CT-genotype,
and 78.8% for homozygous CC-genotype. Patients’ clinical characteristics did not significantly differ
between subcohorts (Table 1), i.e., for serum creatinine concentration or need for dialysis.
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Table 1. Clinical characteristics of acute respiratory distress syndrome (ARDS) patients with genetic variants in the PHD2 gene (SNP rs516651, rs480902) and HIF-2α.
Genotype
(n)
rs516651 rs516651 rs516651 p Value rs480902 rs480902 rs480902 p Value HIF-2α HIF-2α p Value
CC
(n = 208)
CT
(n = 50)
TT
(n = 6) n = 264
CC
(n = 142)
CT
(n = 119)
TT
(n = 10) n = 271
CC
(n = 264)
CG
(n = 1) n = 265
Gender
(women/men; n; %)
89/119
(42.8/57.2)
18/32
(36/64)
0/6
(0/100) 0.084 **
54/88
(38/62)
48/71
(40/60)
8/2
(80/20) 0.033 **
107 /157
(59.5/40.5)
1/0
(100/0) 0.410
Age
(years; median; Q1; Q3) #
44
(33–55)
45
(35–57)
65.5
(56–71) 0.011 *
45
(34–57)
43
(32–54)
43
(34–50) 0.290 *
44
(33–56) 23 0.178
Height
(cm; median; Q1; Q3) #
175
(165–180)
178
(168–185)
178
(171–185) 0.160 *
175
(167–180)
175
(165–183)
170
(163–175) 0.190 *
175
(165–180) 192 0.098
Body weight
(kg; median; Q1; Q3) #
85
(70–90)
80
(70–94)
80
(70–90) 0.644 *
85
(70–90)
85
(70–93)
78
(65–80) 0.322 *
85
(70–90) 86 0.782
Body mass index
(kg·m−2; median; Q1; Q3) #
26.7
(23.4–30.5)
26.3
(23.9–29.4)
24.2
(23.5–26.3) 0.389 *
26.1
(23.4–29.4)
27.3
(23.9–31.2)
26.4
(21.9–28.5) 0.436 *
26.3
(23.9–30.1) 23.3 0.322
Mean arterial blood pressure
(mmHg; median; Q1; Q3) #
80
(72–87)
83
(75–88)
86
(68–98) 0.472 *
80
(72–87)
81
(73–87)
95
(87–121) 0.046 *
110
(90–125) - -
Mean systolic arterial blood pressure
(mmHg; median; Q1; Q3) #
120
(110–130)
120
(115–130)
136
(128–150) 0.126 *
120
(110–129)
120
(110–130)
121
(115–145) 0.330 *
80
(72–87) - -
Heart rate
(min−1; median. Q1; Q3) #
107
(90–123)
113
(99–130)
106
(77–148) 0.648 *
110
(95–120)
110
(90–132)
100
(82–114) 0.569 *
120
(110–130) 110 0.334
Mean pulmonary arterial pressure
(mmHg; median; Q1; Q3) #
35.5
(31–40)
33
(28–39)
38.5
(34–42) 0.261 *
35
(30–41)
35
(29–40)
38
(35–45) 0.416 *
35.5
(30–41) 29 0.321
Lower airway pressure
(median; Q1; Q3) #
18
(15–20)
18
(14–20)
16
(10–18.5) 0.468 *
18
(15–20)
18
(15–20)
15
(10–20) 0.359 *
18
(15–20) 22 0.126
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Table 1. Cont.
Genotype
(n)
rs516651 rs516651 rs516651 p Value rs480902 rs480902 rs480902 p Value HIF-2α HIF-2α p Value
CC
(n = 208)
CT
(n = 50)
TT
(n = 6) n = 264
CC
(n = 142)
CT
(n = 119)
TT
(n = 10) n = 271
CC
(n = 264)
CG
(n = 1) n = 265
Horovitz ratio
(median; Q1; Q3) #
108
(73–195)
95
(72–172)
146
(98–193) 0.614 *
110
(77–201)
106
(68–178)
96
(77–139) 0.517 *
107
(73–187) 115 0.642
Creatinin serum concentration
(mg·dL−1; median; Q1; Q3) #
1.42
(1.00–2.43)
1.27
(0.96–1.89)
1.34
(1.16–1.48) 0.413 *
1.48
(1.01–2.17)
1.33
(1.00–2.75)
1.00
(0.82–1.76) 0.274 *
1.4
(1–2.4) 1.11 0.225
Dialysis (yes/no; %) 115/76(60.2/39.8)
21/24
(53.3/46.7)
5/1
(83.3/16.7) 0.114 **
81/46
(63.8/36.2)
61/51
(54.5/45.5)
5/5
(50/50) 0.288 **
145/98
(59.7/40.3)
0/1
(0/100) 0.759
Infectious variables
White blood cell count
(109·L−1; median; Q1; Q3) #
14.2
(8.9–21.9)
13.4
(9.4–22.2)
9.8
(8.8–15.6) 0.517 *
14.5
(9.2–22.9)
13.4
(8.8–21.1)
12.8
(8.6–22.3) 0.785 *
13.8
(8.8–21.8) 16.4 0.357
Procalcitonin serum concentration
(µg·L−1; median; Q1; Q3) #
4.48
(0.69–28.70)
2.56
(0.85–11.9)
0.71
(0.29–30.13) 0.801 *
2.21
(0.60–16.67)
5.38
(0.93–37.38)
5.34
(1.01–68.55) 0.139 *
3.78
(0.69–26.4) - -
C-reactive protein concentration
(g·L−1; median; Q1; Q3) #
19.9
(13.3–27.5)
17.4
(7.1–28.3)
18.4
(12.8–37.3) 0.435 *
18.4
(11.50–24.8)
20.7
(12.8–32.7)
19.0
(8.3–24.1) 0.286 *
19.6
(11.8–27.8) 28.2 0.967
Disease severity
SAPS II ## (mean ± SD) + 42.5(30–58)
39.5
(30–60)
41.5
(32–71) 0.836 *
43
(31–61)
42
(30–60)
27
(19–42) 0.099 *
43
(31–60) 42 0.482
SOFA ++ (mean ± SD) + 14(11–20)
13
(10–16)
13.5
(10–20) 0.368 *
15
(12–22)
13
(10–18)
14
(11–22) 0.095 *
14
(11–20) 12 0.433
Hospital stay
(d; mean ± SD) +
22
(14–38)
22
(14–34)
18
(13–24) 0.742 *
24
(13–39)
21
(14–33)
18
(14–26) 0.596 *
22
(14–37) 14 0.548
30-day mortality (%) 48 (23) 16 (32) 5 (83.3) 0.002 ** 39 (27.5) 32 (26.9) 0 (0) 0.158 ** 70 (26.5) 0 (0) -
Biometric data, infectious variables and disease severity of 264 ARDS patients. Data were documented at the time of first diagnosing ARDS. * Numbers (n); p Value based on
Kruskal-Wallis-Test; + mean ± standard deviation; # median with 25% and 75% quartiles (median; Q1; Q3); ** Numbers; p Value based on Pearson-Chi-quadrat tests; ## Simplified Acute
Physiology Score II; ++ Sequential Organ Failure Assessment score.
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Kaplan-Meier-analyses (Figure 1) showed a significantly higher mortality for the homozygous
TT-genotype (p = 0.001).
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Figure 1. lan–Meier plot of 30-day mortality of acute respiratory distress syndrome (ARDS)
patients stratified for PHD2 (rs516651) genotypes. Kaplan-Meier estimators for the three subgroups
for 264 patients. CC = homozygous CC-genotype (n = 208); CT = heterozygous C -genotype (n = 50);
TT = homozygous TT-genotype (n = 6). For 8 patients, genotyping results ere unclear and patients
were excluded from analysis; log-rank-test: p = 0.001.
Most important, ltivariate ox-regression-analyses (Table 2) revealed that the rs516651
TT-genotype is an independent predictor of 30-day mortality from ARDS and carries a 3.34 times
higher mortality risk, when including known risk factors for mortality from ARDS like gender, age,
need for renal replacement therapy, or SAPS II. Five of 6 (83.3%) ARDS patients with the rs516651
TT-genotype did not survive 30 days.
Table 2. Cox-regression analyses of 264 ARDS patients with genetic variants in the Prolylh droxylase 2
gene (rs516651).
Covariables HR (95% CI) p Value
rs516651, CT vs. CC 1.71 (0.89–3.29) 0.11
rs516651, TT vs. CC 3.34 (1.09–10.22) 0.034
Age, per year 1.01 (0.99–1.036) 0.40
Gender, male vs. female 0.92 (0.49–1.74) 0.80
Dialysis, yes vs. no 0.94 (0.44–2.01) 0.87
SAPS II, per point 1.03 (1.01–1.04) 0.0032
SOFA 1.01 (0.98–1.04) 0.43
PCT 1.002 (1.00–1.003) 0.038
Number of patients with missing data for the different covariables were: Dialysis (n = 22), Simplified Acute
Physiology Score II (SAPS II) (n = 12), Sequential Organ Failure Assessment sco (SOFA) (n = 12), procalciton n
(PCT) (n = 67). The Table displays hazard ratio (HR) point estimates, 95% confidence intervals (95% CI), and p Values
derived from Cox–regression- analyses.
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2.3. Prolylhydroxylase 2 (T/C; rs480902) Polymorphism
Allele frequencies were 3.7% for homozygous TT-genotype, 43.9% for heterozygous CT-genotype,
and 52.4% for homozygous CC-genotype. Patients’ clinical characteristics did not differ between
subcohorts (Table 1). Kaplan-Meier analyses and log-rank test (p = 0.199) revealed no impact of the
specific genotype on 30-day mortality from ARDS, even in the univariate analysis.
3. Discussion
In this study, we show that the functionally active PHD2 SNP rs516651 [18], located in the key
pathway for the hypoxic-inflammatory response, is associated with increased 30-day mortality in ARDS
patients. In contrast, the PHD2 SNP rs480902 is not. Furthermore, the HIF-2α SNP [ch2: 46441523(hg18)]
GG-genotype was neither present in our ARDS patients of Caucasian heritage nor in healthy Caucasian
blood donors.
Hypoxia-inducible factors and HIF degrading PHDs are key regulators of the human response
to low ambient oxygen [19] and also provide a link between hypoxia and the inflammatory
response [9]. HIF degrading prolylhydroxylase 2 SNPs are known to be associated with erythrocytosis
in humans [10] and PHD2 deficiency evokes erythrocytosis by activating the renal erythropoietin
pathway in mice [20]. Furthermore, the lack of PHD2 leads to defective vascular growth [21]. Moreover,
recent studies have shown that genetic variants in HIF-2α gene and PHD2 influence the hypoxic
inflammatory response, resulting in altered heart rate, arterial oxygen saturation, incidence of chronic
mountain sickness or erythrocytosis [6,22,23].
Our study is the first to analyze the occurrence of these three genetic variants (HIF-2α SNP:
rs46441523; PHD2 SNP rs516651 and rs480902) in Caucasians with ARDS and their potential association
with death from ARDS.
T-allele carriers of the PHD2 SNP rs516651 are quite common in Caucasian ARDS patients
(TT-genotype: 2.3%; CT-genotype 18.9%) and with homozygous TT-genotype carrying a significantly
greater mortality compared to CC-genotypes. As homozygous TT-genotypes were all male patients
and older compared to the other genotypes, in a next step we performed a multivariate Cox-regression
analysis, including age, gender, need for dialysis as well as other clinical confounders known to
carry a higher risk for death from ARDS to our analysis. Thus, even when adjusting for these
variables, the TT-genotype of the PHD2 SNP rs516651 is an independent predictor for 30-day mortality
in ARDS. Of note, increased pulmonary artery pressure, often present in ARDS patients and to
a varying extent due to hypoxic pulmonary vasoconstriction (the Euler-Liljestrand-mechanism),
also is a risk factor for pulmonary edema in high-altitude residents [24]. Of note, genotyping of
high-altitude residents adapted to hypoxia, like Tibetans, did not reveal the presence of T-alleles,
possibly due to an evolutionary selection bias [15]. Thus, the PHD2 SNP rs516651 polymorphism may
impact on adaptation to hypoxia both in high-altitude-residents and patients with ARDS. However,
further studies are needed to confirm our results and to analyze the underlying pathomechanisms.
Showing that genetic variants depict a specific phenotype not only in high-altitude residents but
also in ARDS patients is crucial before finally judging the relevance of this particular SNP on
ARDS pathogenesis.
We also analyzed a further genetic variant in the PHD2 gene (SNP rs480902) but this genetic
variant did not impact on ARDS mortality in our cohort. Wu et al. showed a correlation between single
nucleotide polymorphisms in hypoxia-related genes like the PHD2 (SNPrs480902) and susceptibility
to acute high-altitude pulmonary edema (HAPE). They found that the HAPE cases had a significant
higher T-allele frequency than the control group [25]. Buroker et al. described phenotypical differences
between Han Chinese with acute mountain sickness (AMS) in the rs480902 SNP. They found a
significant correlation between (rs480902) SNP (C/T) and heart rate, arterial oxygen saturation of
hemoglobin, and the hematocrit in the AMS-group. The CC- and TT-genotypes had a significantly
higher heart rate compared to the CT-genotype while patients with the CC-genotype had a significantly
greater arterial oxygen saturation of hemoglobin than those with either the CT- or TT-genotypes in the
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Han AMS study group. AMS Chinese with CT- and TT-genotypes had a significantly higher hematocrit
than those with CC-genotypes. It seems that the various genotypes have different mechanisms of
compensation in hypoxia. In our study, however, we did not find such differences in the ARDS cohort.
However, mice with PHD2-deficiency show increased angiogenesis due to upregulated vascular
endothelial growth factor-A (VEGF-A) serum concentrations. Furthermore, erythropoietin, which
stimulates angiogenesis and erythropoiesis, was dramatically overexpressed in PHD2-deficient mice.
Thus, PHD2 is a major negative regulator for vascular growth. Additionally, PHD2 knockout in mice
inhibits tumor necrosis factor α (TNFα) and intercellular Adhesion Molecule 1 (ICAM-1) expression
and decreases both cell apoptosis and macrophage infiltration [21]. Even when PHD2 alterations
impact on the inflammatory response in mice or the hypoxic response in high-altitude residents,
analyzed PHD2 genetic variants did neither impact on serum inflammatory variables like procalcitonin
(PCT) or C-reactive Protein (CRP) serum concentrations nor on 30-day mortality from ARDS in our
patient cohort. It is known that both hypoxia and inflammation alter the hypoxic-inflammatory
response, thus alternative pathways might be induced and could be an effect of those SNPs. To further
elucidate this analysis of the genotype dependent PHD2 protein activity and target gene expression in
patients with and without ARDS should be done in a subsequent study.
Third, we analyzed the frequency of the HIF-2α gene genetic variant rs46441523. Surprisingly,
GG-genotypes did not exist in our Caucasians with ARDS, and only a single (surviving) individual
carrying a CG-genotype was observed. Since the frequency distribution of alleles in ARDS patients and
blood donors were similar, these data indicate that, at least in our region, this HIF-2α polymorphism
does not exist in Caucasians either with or without ARDS. It is already know about the HIF-2α
polymorphism that it changes very fast. Between Tibetan and Han samples one SNP at Endothelial
PAS domain-containing protein 1 (EPAS1) shows a 78% frequency difference, representing the fastest
allele frequency change observed at any human gene to date [26]. Thus, further studies are warranted
to analyze allele frequency distributions in different ethnicities and diseases.
Our study has limitations. First, although we included as many as 272 ARDS patients, our cohort
might still be considered small. Second, we included ARDS patients over a long time period, and
systemic changes in patient care cannot be entirely ruled out. However, this likely is of minor
importance as changes in the standard of care would have influenced all patients similarly irrespective
of their genotype, and the intensity in charge was blind to specific patients’ genotypes. In fact,
considering this timing, the finding that the homozygous TT-genotype of the PHD2 SNP rs516651
carried a significantly greater mortality compared to the CC-genotype is even more robust. However,
the most important limitation of our study is that we cannot provide mechanistic explanations. Thus,
further studies are necessary to analyze genotype-dependent immune cell function, intracellular
signaling cascades, and pulmonary vascular tone in ARDS.
The rs480902 SNPs did not meet the Hardy-Weinberg equilibrium, with a p Value of 0.01.
According to Chen, deviations from the Hardy-Weinberg equilibrium proportions suggest that at least
one of the standard underlying assumptions for the test (non-overlapping generations, large population
size with random mating, no mutation, no migration, and no selection) may be violated. Thus,
the distribution of this genetic variant should be analyzed in a larger cohort.
4. Materials and Methods
4.1. Patients
The prospective study was reviewed and approved by the Medical Faculty’s ethics committee
(No. 06-3078, 1 October 2009, Medical Faculty of the University of Duisburg-Essen, Essen, Germany)
and registered in the German clinical trials database (DRKS No.: DRKS00011661). Two hundred
seventy two adult patients with ARDS admitted to our intensive care unit (ICU) at the University
Hospital Essen, Germany, between 2004 and 2014 were screened for study inclusion. ARDS patients
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were considered eligible when they fulfilled the definition for ARDS [18]. Patients who refused or
withdrew study participation, and all individuals with non-Caucasian ethnicity were excluded.
4.2. Samplings
Arterial blood samples were taken for blood tests, microbiology cultures, and later genotyping
within the first 24 h after diagnosing ARDS. Furthermore, SAPS II (Simplified Acute Physiology
Score II) [27], results of blood cultures, length of hospitalization, and 30-day mortality were
assessed [15,28,29]. As the HIF-2α-polymorphism was not present in Caucasian ARDS patients, in a
second step, we investigated the allele frequencies in a cohort of 100 healthy blood donors (47 females,
53 males, median age: 45 years (Q1; Q3: 30; 59)), following ethics committee approval and informed
written consent, to rule out that allele frequencies for the HIF-2α-polymorphism vary between ARDS
patients and healthy volunteers.
4.3. Genotyping
The PHD2 (T/C) SNP (rs480902) and the PHD2 (C/T) SNP (rs516651) were detected using Taqman
SNP Genotyping Assays (Assay-ID: C___2816291_10; C___2816320_10). Genotyping was performed
with a PCR System (StepOnePlus™, Applied Biosystem, Waltham, MA, USA) at standard conditions
(60 ◦C for 30 min followed by 95 ◦C for 10 s, and for 15 s at 92 ◦C and with 50 cycles at 60 ◦C for 1 s).
Of 272 patients genotyping the rs516651 SNP we obtained 264 secured genotyping results whereas we
were not able to determine genotypes in 8 cases.
The HIF-2α (SNP C/G [ch2: 46441523(hg18)]) genotype was determined using restriction digest
of a 377 bp PCR amplicon with BsmAI (New England Biolabs, Inc., Ipswich, MA, USA). The SNP was
included in its cut site. The digested amplicon resulted in 130 and 247 bp fragments in the presence of
the C nucleotide or an uncut 377 bp fragment in the presence of the G nucleotide as Buroker et al. have
done it first 2012. The DNA fragment sizes were visualized using a 1.5% Tris-Borat EDTA agarose gel.
4.4. Statistical Analyses
Data are presented as medians with interquartile ranges (IQR) unless indicated otherwise.
For independent samples the Wilcoxon Kruskal-Wallis signed rank test was used. An a priori alpha
error p of less than 0.05 was considered statistically significant. In a first step, Hardy-Weinberg-
equilibrium was analyzed using the Court Lab calculator 2005–2008 (Court MH; Court-laboratory
Hardy-Weinberg calculator; Tufts University; www.tufts.com, Medford, MA, USA for MS Excel)
(rs516651; p = 0.1611; rs480902; p = 0.0127).
Afterwards, we investigated associations between the clinical characteristics of the genetic variants
with overall 30-day survival, defined as the interval from time of first diagnosing ARDS until death.
Patients alive after the 30-day follow-up were regarded as censored. Kaplan-Meier estimators were
used to display the overall 30-day survival data in the respective subcohorts followed by log-rank tests
for comparison. Finally, we performed multivariate Cox-regression-analyses to assess the impact of
the respective genotypes (PHD2 rs516651/rs480902), sex, age, Simplified Acute Physiology Score II,
Sequential Organ Failure Assessment score, requirement for continuous hemofiltration/dialysis and
procalcitonin concentration as predictors for 30-day survival. Statistical analyses were performed
using SPSS 21.0 (SPSS Inc., Chicago, USA). For the multivariable Cox-regression-models SAS PHREG
Procedure was used (version 9.3, SAS Institute, Cary, NC, USA).
5. Conclusions
In conclusion, the genetic SNP rs516651 in the PHD2 gene is an independent predictor for 30-day
mortality in ARDS patients with a Caucasian heritage, whereas the rs480902 SNP is not. Furthermore,
we could show that the HIF-2α GG-genotype [SNP: ch2: 46441523(hg18)] is not present in Caucasians
with or without ARDS, in contrast to Han Chinese. Further studies should be conducted to analyze to
what extent the PHD2 SNP rs516651 alters PHD2 protein expression and activity.
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